Change in Preferred Drug List Status for Antihyperuricemics Drug Class
Date: April 25, 2024
Attention: All Providers
Effective date: April 22, 2024
Call to action: Effective April 22, 2024, the Texas Health and Human Services (HHS) removed non-preferred status from brand name Mitigare products. This is in response to the discontinuation of the brand products Colcrys by the manufacturer.
The preferred status of the brand name Colcrys will not change to allow any remaining stock to be used.
How this impacts providers: The change will allow providers to prescribe the generic without requiring PDL prior authorization at this time and continue accessing necessary medication for their patients.
Please see below for the list of impacted drugs (of note, the approval is NDC-specific):
| Preferred Medication NDC | Preferred Medication | Type of Change | Effective Date |
| 59467031801 | MITIGARE 0.6 MG CAPSULE | Brand now preferred | April 22,2024 |
| 59467031810 | MITIGARE 0.6 MG CAPSULE | Brand now preferred | April 22,2024 |
| 59467031830 | MITIGARE 0.6 MG CAPSULE | Brand now preferred | April 22,2024 |
Next step for Providers: Prescribers are encouraged to proactively obtain a prescription for the preferred alternatives to avoid disruption in patient’s therapy. Prescribers should share this communication with their staff.
If you have any questions, please email TCHP Pharmacy at: tchppharmacy@texaschildrens.org.
For access to all provider alerts,log into:
www.thecheckup.org or www.texaschildrenshealthplan.org/for-providers.